The randomized trial “Bupropion for Smoking Cessation” is in my opinion a flawed study.1 Bupropion hydrochloride, an antidepressant, functions as an anticraving agent. When one craves cigarettes, the craving does not occur while smoking, but when cigarettes are absent. Nicotine 7-mg patches were being administered during the seventh and eighth weeks; this is equivalent to smoking one third of a pack daily, except that the nicotine was being delivered at a steady rate instead of by bolus. The craving for nicotine would be expected to peak after withdrawal of the nicotine patches (ie, after 8 weeks), and that is precisely when the bupropion hydrochloride should have been on board at the 300-mg dose if meaningful anticraving action was sought. In addition, it should have been continued for another 1 to 3 weeks to improve the short-term success rate. Instead, bupropion treatment was discontinued 1 week before the nicotine patches ran out. This design could be predicted to fail.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.